Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 5:31 PM
Ignite Modification Date: 2025-12-24 @ 5:31 PM
NCT ID: NCT05855668
Eligibility Criteria: Inclusion Criteria: 1. Patient has been referred to or intends to participate in either the AUD or CUD Integrated Care Pathway (and is therefore willing to participate in group psychotherapy). 2. Able to communicate and provide informed consent in English. 3. 18 years of age or older. 4. Willing and able to safely abstain from substances (other than nicotine or tobacco products), including alcohol and cannabis, for 12 hours prior to the eligibility and task-based assessments. 5. Meets DSM-5 diagnostic criteria for AUD (AUD group) or CUD (CUD group) 6. Meets criteria for risky drinking, defined as \> 10 drinks per week for females and \> 15 drinks per week for males on average over the past 30 days (AUD group) or daily or near-daily cannabis use over the past 30 days, defined as ≥ 4 days of cannabis use per week on average (CUD group) Exclusion Criteria: 1. Active suicidal ideation at time of assessment. 2. Suicide attempt within the past month. 3. Unstable psychiatric or medical status (e.g., acute psychosis or mania) or unstable use of another substance that may interfere with participation in groups (e.g. active fentanyl use). 4. Enrollment in another study that conflicts with the procedures or scientific integrity of this study. 5. Individuals planning to be out of the province for a substantial amount of time during the treatment period will not be permitted to enroll.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT05855668
Study Brief:
Protocol Section: NCT05855668